Lipella Re-Signs Manufacturing Agreement with Cook MyoSite for Clinical Pipeline Support

• Lipella Pharmaceuticals has renewed its manufacturing collaboration with Cook MyoSite.

• The agreement supports Chemistry, Manufacturing and Control (CMC) documentation for Lipella’s clinical candidates LP-10 and LP-310.

Clinical-stage biotechnology company Lipella Pharmaceuticals Inc. has announced the renewal of its manufacturing collaboration agreement with Cook MyoSite, Inc. The partnership will support the development of Chemistry, Manufacturing and Control (CMC) documentation for two of Lipella’s clinical-stage therapies, LP-10 and LP-310.

The renewed agreement comes as Lipella advances its drug candidates towards later development stages and potential commercialisation. LP-10 and LP-310 are part of Lipella’s maturing clinical pipeline focused on treating diseases with significant unmet medical needs.

Commenting on the collaboration, Dr. Jonathan Kaufman, CEO and Co-Founder of Lipella, said: “We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.”

Cook MyoSite, which has an ongoing relationship with Lipella, also plays a governance role. Ryan Pruchnic, Managing Vice President of Cook MyoSite and a member of Lipella’s Board of Directors, stated: “Our team is committed to ensuring high standards of safety, quality and execution, to support Lipella’s clinical progress.”